Advertisement

CNS Drugs

, Volume 32, Issue 8, pp 735–746 | Cite as

Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders

  • Michael J. MarmuraEmail author
  • Aliza S. Kumpinsky
Review Article

Abstract

Anti-epileptic drugs are among the most effective drugs for migraine prophylaxis, and will likely continue to have a role even as new therapies emerge. Topiramate and valproate are effective for the preventive treatment of migraine, and other medications such as gabapentin or lamotrigine may have a role in the treatment of those with allodynia or frequent aura, respectively. Oxcarbazepine, carbamazepine, phenytoin, gabapentin, and others may alleviate pain in trigeminal neuralgia. While many anti-epileptic drugs can be effective in those with migraine or other headaches, most of these agents can potentially cause serious side effects. In particular, valproate, topiramate, carbamazepine, and phenytoin may lead to adverse outcomes for infants of exposed mothers. Valproate should not be given to women of childbearing potential for migraine prevention.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were received for the preparation of this article.

Conflict of interest

Michael J. Marmura has received compensation for consultations from Teva, Supernus, Amgen, GammaCore, Promius, Alder, and Valeant. He has also received compensation for speaker bureau participation from Amgen. Aliza S. Kumpinsky has no conflicts of interest directly relevant to the contents of this article.

References

  1. 1.
    Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57(1):165–78.PubMedGoogle Scholar
  2. 2.
    Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–57.PubMedGoogle Scholar
  3. 3.
    Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl. 2):S1–59.PubMedGoogle Scholar
  4. 4.
    Bordini CA, Mariano da Silva H, Garbelini RP, Teixeira SO, Speciali JG. Effect of preventive treatment on health-related quality of life in episodic migraine. J Headache Pain. 2005;6(5):387–91.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43(3):171–8.PubMedGoogle Scholar
  6. 6.
    Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache. 2005;45(8):1023–30.PubMedGoogle Scholar
  7. 7.
    Lason W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep. 2013;65(4):787–801.PubMedGoogle Scholar
  8. 8.
    Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 2007;28(4):188–95.PubMedGoogle Scholar
  9. 9.
    Rizzoli PB. Acute and preventive treatment of migraine. Continuum (Minneap Minn). 2012;18(4):764–82.Google Scholar
  10. 10.
    Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652–61.PubMedGoogle Scholar
  11. 11.
    Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain. 2013;14:62.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Durham PL, Niemann C, Cady R. Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache. 2006;46(8):1291–5.PubMedGoogle Scholar
  13. 13.
    Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008;71(15):1183–90.PubMedGoogle Scholar
  14. 14.
    Lainez MJ, Pascual J, Santonta JM. Topiramate in the prophylactic treatment of cluster headache. Cephalalgia. 2001;21:500.Google Scholar
  15. 15.
    Stacey BR, Glanzman RL. Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. Clin Ther. 2003;25(10):2597–608.PubMedGoogle Scholar
  16. 16.
    Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl. 1):S3–9.PubMedGoogle Scholar
  17. 17.
    Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007;47(3):402–12.PubMedGoogle Scholar
  18. 18.
    Rawls SM, Thomas T, Adeola M, Patil T, Raymondi N, Poles A, et al. Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav. 2009;93(4):363–7.PubMedGoogle Scholar
  19. 19.
    Nakamura J, Tamura S, Kanda T, Ishii A, Ishihara K, Serikawa T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol. 1994;254(1–2):83–9.PubMedGoogle Scholar
  20. 20.
    Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(Suppl. 1):S35–9.PubMedGoogle Scholar
  21. 21.
    Coomans CP, Geerling JJ, van den Berg SA, van Diepen HC, Garcia-Tardon N, Thomas A, et al. The insulin sensitizing effect of topiramate involves KATP channel activation in the central nervous system. Br J Pharmacol. 2013;170(4):908–18.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome: Topiramate YL Study Group. Neurology. 1999;52(9):1882–7.PubMedGoogle Scholar
  23. 23.
    Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–53.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41(10):968–75.PubMedGoogle Scholar
  25. 25.
    Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–73.PubMedGoogle Scholar
  26. 26.
    Silberstein SD, Neto W, Schmitt J. Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490–5.PubMedGoogle Scholar
  27. 27.
    Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153–62.PubMedGoogle Scholar
  28. 28.
    Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398–408.PubMedGoogle Scholar
  29. 29.
    Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943–50.PubMedGoogle Scholar
  30. 30.
    Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46(4):642–8.PubMedGoogle Scholar
  31. 31.
    Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008;118(5):301–5.PubMedGoogle Scholar
  32. 32.
    Marmura MJ, Hopkins M, Andrel J, Young WB, Biondi DM, Rupnow MF, et al. Electronic medical records as a research tool: evaluating topiramate use at a headache center. Headache. 2010;50(5):769–78.PubMedGoogle Scholar
  33. 33.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.PubMedGoogle Scholar
  34. 34.
    Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29(10):1021–7.PubMedGoogle Scholar
  35. 35.
    Celebisoy N, Gokcay F, Sirin H, Akyurekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116(5):322–7.PubMedGoogle Scholar
  36. 36.
    Krymchantowski AV, Jevoux Cda C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache. 2012;52(1):129–32.PubMedGoogle Scholar
  37. 37.
    Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110(10):979–84.PubMedGoogle Scholar
  38. 38.
    Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976–84.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Borron SW, Woolard R, Watts S. Fatal heat stroke associated with topiramate therapy. Am J Emerg Med. 2013;31(12):1720.e5–6.PubMedGoogle Scholar
  40. 40.
    Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, Simonetti GD, Ramelli GP, Bianchetti MG, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77(6):958–64.PubMedGoogle Scholar
  41. 41.
    Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. Cephalalgia. 2002;22(8):659–63.PubMedGoogle Scholar
  42. 42.
    Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia. 2002;43(9):1072–5.PubMedGoogle Scholar
  43. 43.
    Brandes JL. Practical use of topiramate for migraine prevention. Headache. 2005;45(Suppl. 1):S66–73.PubMedGoogle Scholar
  44. 44.
    Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44(3):339–47.PubMedGoogle Scholar
  45. 45.
    Romigi A, Cervellino A, Marciani MG, Izzi F, Massoud R, Corona M, et al. Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol. 2008;15(2):190–5.PubMedGoogle Scholar
  46. 46.
    Marino SE, Pakhomov SV, Han S, Anderson KL, Ding M, Eberly LE, et al. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory. Epilepsy Behav. 2012;24(3):365–72.PubMedGoogle Scholar
  47. 47.
    Ahmed GF, Marino SE, Brundage RC, Pakhomov SV, Leppik IE, Cloyd JC, et al. Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. Br J Clin Pharmacol. 2015;79(5):820–30.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Evans RW. Reversible palinopsia and the Alice in Wonderland syndrome associated with topiramate use in migraineurs. Headache. 2006;46(5):815–8.PubMedGoogle Scholar
  49. 49.
    Sierra-Hidalgo F, de Pablo-Fernandez E. Palinopsia induced by topiramate and zonisamide in a patient with migraine. Clin Neuropharmacol. 2013;36(2):63–4.PubMedGoogle Scholar
  50. 50.
    Ho JD, Keller JJ, Tsai CY, Liou SW, Chang CJ, Lin HC. Topiramate use and the risk of glaucoma development: a population-based follow-up study. Am J Ophthalmol. 2013;155(2):336–341.e1.PubMedGoogle Scholar
  51. 51.
    Yamamoto Y, Takahashi Y, Imai K, Kagawa Y, Inoue Y. Effect of CYP inducers/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring. Ther Drug Monit. 2017;39(1):55–61.PubMedGoogle Scholar
  52. 52.
    Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38(3):317–23.PubMedGoogle Scholar
  53. 53.
    Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):405.e1–7.PubMedGoogle Scholar
  54. 54.
    Ohman I, Vitols S, Luef G, Soderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia. 2002;43(10):1157–60.PubMedGoogle Scholar
  55. 55.
    Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–9.PubMedGoogle Scholar
  56. 56.
    Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695–714.PubMedGoogle Scholar
  57. 57.
    Li Y, Zhang Q, Qi D, Zhang L, Yi L, Li Q, et al. Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-small ka, CyrillicB. J Headache Pain. 2016;17:49.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Abou-Khalil BW. Antiepileptic drugs. Continuum (Minneap Minn). 2016;22(1 Epilepsy):132–56.Google Scholar
  59. 59.
    Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44(4):647–51.PubMedGoogle Scholar
  60. 60.
    Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81–4.PubMedGoogle Scholar
  61. 61.
    Klapper JA. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103–8.PubMedGoogle Scholar
  62. 62.
    Omtzigt JG, Los FJ, Grobee DE, Pijpers L, Jahoda MG, Brandenburg H, et al. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology. 1992;42(S5):119–25PubMedGoogle Scholar
  63. 63.
    Pai SA, Kshirsagar N. A critical evaluation of pharmacogenetic information in package inserts for selected drugs marketed in India and its comparison with US FDA-approved package inserts. J Clin Pharmacol. 2016;56(10):1232–42.PubMedGoogle Scholar
  64. 64.
    Meijboom RW, Grootens KP. Dispensability of annual laboratory follow-up after more than 2 years of valproic acid use: a systematic review. CNS Drugs. 2017;31(11):939–57.PubMedGoogle Scholar
  65. 65.
    Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438–45.PubMedGoogle Scholar
  66. 66.
    Farooq F, Sahib Din J, Khan AM, Naqvi S, Shagufta S, Mohit A. Valproate-induced hyperammonemic encephalopathy. Cureus. 2017;9(8):e1593.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Felker D, Lynn A, Wang S, Johnson DE. Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. Exp Rev Clin Pharmacol. 2014;7(2):211–8.Google Scholar
  68. 68.
    Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009;47(2):101–11.Google Scholar
  69. 69.
    Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23(10):961–2.PubMedGoogle Scholar
  70. 70.
    Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci. 2007;28(5):220–8.PubMedGoogle Scholar
  71. 71.
    Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter. 2000;151(3):145–8.PubMedGoogle Scholar
  72. 72.
    Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41(2):119–28.PubMedGoogle Scholar
  73. 73.
    Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010609.Google Scholar
  74. 74.
    Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013;33(2):101–11.PubMedGoogle Scholar
  75. 75.
    Yuan M, Zhou HY, Xiao ZL, Wang W, Li XL, Chen SJ, et al. Efficacy and safety of gabapentin vs. carbamazepine in the treatment of trigeminal neuralgia: a meta-analysis. Pain Pract. 2016;16(8):1083–91.PubMedGoogle Scholar
  76. 76.
    Ahmed F. Chronic cluster headache responding to gabapentin: a case report. Cephalalgia. 2000;20:252–3.PubMedGoogle Scholar
  77. 77.
    Leandri M, Luzzani M, Cruccu G, Gottlieb A. Drug-resistant cluster headache responding to gabapentin: a pilot study. Cephalalgia. 2001;21:744–6.PubMedGoogle Scholar
  78. 78.
    Trucco M. Nummular headache: another case treated with gabapentin. J Headache Pain. 2007;8(2):137–8.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–9.PubMedGoogle Scholar
  80. 80.
    Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565–70.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Gutierrez-Garcia JM. SUNCT syndrome responsive to lamotrigine. Headache. 2002;42(8):823–5.PubMedGoogle Scholar
  82. 82.
    Bou Ghannam A, Pelak VS. Visual snow: a potential cortical hyperexcitability syndrome. Curr Treat Options Neurol. 2017;19(3):9.PubMedGoogle Scholar
  83. 83.
    Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76(12):1730–2.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Pascual J, Caminero AB, Mateos V, Roig C, Leira R, Garcia-Monco C, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache. 2004;44(10):1024–8.PubMedGoogle Scholar
  85. 85.
    Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17(2):109–12.PubMedGoogle Scholar
  86. 86.
    Leone M, Rigamonti A, Usai S, Damico D, Grazzi L, Bussone G. Two new SUNCT cases responsive to lamotrigine. Cephalalgia. 2000;20(9):845–7.PubMedGoogle Scholar
  87. 87.
    Zidverc-Trajkovic J, Vujovic S, Sundic A, Radojicic A, Sternic N. Bilateral SUNCT-like headache in a patient with prolactinoma responsive to lamotrigine. J Headache Pain. 2009;10(6):469–72.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Abe Y, Yasugawa S, Miyamoto K, Terao T. Valproate as a risk factor for lamotrigine discontinuation. J Affect Disord. 2013;150(3):1197–9.PubMedGoogle Scholar
  89. 89.
    Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol. 2011;106(3):1227–39.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Young WB, Shaw J, Bloom M, Gebeline-Myers C. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects. Headache. 2008;48(10):1490–8.PubMedGoogle Scholar
  91. 91.
    Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol. 2006;29(6):338–42.PubMedGoogle Scholar
  92. 92.
    Pizza V, Busillo V, Agresta A, Bisogno A, Capasso A. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem. 2011;11(1):31–4.PubMedGoogle Scholar
  93. 93.
    Pakalnis A, Kring D, Meier L. Levetiracetam prophylaxis in pediatric migraine: an open-label study. Headache. 2007;47(3):427–30.PubMedGoogle Scholar
  94. 94.
    Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004;44(3):238–43.PubMedGoogle Scholar
  95. 95.
    Drake ME, Greathouse NI, Armentbright AD, Renner JB. Levetiracetam for preventive treatment of migraine. Cephalalgia. 2001;21(4):373.Google Scholar
  96. 96.
    Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;70(7):548–55.PubMedGoogle Scholar
  97. 97.
    Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J. 1970;44(4):75–80.PubMedGoogle Scholar
  98. 98.
    Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol. 1987;26:73–83.PubMedGoogle Scholar
  99. 99.
    Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1989;52:472–6.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Remillard G. Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia. 1994;35(Suppl. 3):28–9.Google Scholar
  101. 101.
    Zakrzewska JM, Patsalos PN. Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia. Pain. 2002;95(3):259–66.PubMedGoogle Scholar
  102. 102.
    Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.PubMedGoogle Scholar
  103. 103.
    Besi E, Boniface DR, Cregg R, Zakrzewska JM. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). J Headache Pain. 2015;16:563.PubMedGoogle Scholar
  104. 104.
    Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976–8.PubMedGoogle Scholar
  105. 105.
    He N, Min FL, Shi YW, Guo J, Liu XR, Li BM, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure. 2012;21(8):614–8.PubMedGoogle Scholar
  106. 106.
    Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genom. 2014;24(2):94–112.Google Scholar
  107. 107.
    Zakrzewska JM, Patsalos PN. Drugs used in the management of trigeminal neuralgia. Oral Surg Oral Med Oral Pathol. 1992;74(4):439–50.PubMedGoogle Scholar
  108. 108.
    Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13(Suppl. 1):S5–9 (discussion S10).PubMedGoogle Scholar
  109. 109.
    Drake ME, Greathouse NI, Armenthright AD, Renner JB. Zonisamide in the prophylaxis of migraine headache. Cephalalgia. 2001;21:374.Google Scholar
  110. 110.
    Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26(10):1199–202.PubMedGoogle Scholar
  111. 111.
    Villani V, Ciuffoli A, Prosperini L, Sette G. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache. 2011;51(2):287–91.PubMedGoogle Scholar
  112. 112.
    Walls TH, Grindrod SC, Beraud D, Zhang L, Baheti AR, Dakshanamurthy S, et al. Synthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent. Bioorg Med Chem. 2012;20(17):5269–76.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Millichap JG. Recurrent headaches in 100 children: electroencephalographic abnormalities and response to phenytoin (Dilantin). Childs Brain. 1978;4(2):95–105.PubMedGoogle Scholar
  114. 114.
    Robbins L. Posttraumatic headache with scintillating scotoma treated with phenytoin (Dilantin). Headache. 1989;29:515–6.PubMedGoogle Scholar
  115. 115.
    Tate R, Rubin LM, Krajewski KC. Treatment of refractory trigeminal neuralgia with intravenous phenytoin. Am J Health Syst Pharm. 2011;68(21):2059–61.PubMedGoogle Scholar
  116. 116.
    Chua HC, Venketasubramanian N, Tan CB, Tjia H. Paradoxical seizures in phenytoin toxicity. Singapore Med J. 1999;40(4):276–7.PubMedGoogle Scholar
  117. 117.
    Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Yu J, Smith KJ, Brixner DI. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs. 2010;24(8):695–712.PubMedGoogle Scholar
  119. 119.
    Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–45.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Romoli M, Costa C, Siliquini S, Corbelli I, Eusebi P, Bedetti C, et al. Antiepileptic drugs in migraine and epilepsy: who is at increased risk of adverse events? Cephalalgia. 2018;38(2):274–82.PubMedGoogle Scholar
  121. 121.
    Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85(3):283–8.PubMedGoogle Scholar
  122. 122.
    Hutchinson S, Marmura MJ, Calhoun A, Lucas S, Silberstein S, Peterlin BL. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache. 2013;53(4):614–27.PubMedPubMedCentralGoogle Scholar
  123. 123.
    Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21(7):666–75.PubMedGoogle Scholar
  124. 124.
    Hou M, Xing H, Cai Y, Li B, Wang X, Li P, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18(1):42.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Zhu S, Marmura MJ. Non-invasive neuromodulation for headache disorders. Curr Neurol Neurosci Rep. 2016;16(2):11.PubMedGoogle Scholar
  126. 126.
    Ong JJY, Wei DY, Goadsby PJ. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs. 2018;78(4):411–37.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Neurology, Jefferson Headache CenterThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations